Royalty Pharma plc (RPRX)

Royalty Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	764.96	858.98	1,135	42.83	619.73	975.04
Depreciation & Amortization	2.66	-	-	5.67	23	23.06
Other Amortization	22.03	19.56	20.5	21.36	20.16	11.72
Asset Writedown & Restructuring Costs	-	-	-	615.83	-	65.05
Loss (Gain) From Sale of Investments	26.69	-194.46	-317.98	40.26	30.21	-265.67
Loss (Gain) on Equity Investments	-43.34	-16.22	-10.06	48.12	53.87	-2.13
Stock-Based Compensation	164.65	2.34	2.36	2.17	2.44	5.43
Provision & Write-off of Bad Debts	-154.91	732.46	560.66	904.24	452.84	230.84
Other Operating Activities	-1,579	-1,670	-1,609	-2,076	-1,484	-1,207
Change in Accounts Receivable	3,216	2,983	3,201	2,507	2,296	2,122
Change in Accounts Payable	8.73	-2.29	6.24	2.29	-4.59	-0.77
Change in Other Net Operating Assets	-22.87	55.67	-0.85	30.38	8.4	76.36
Operating Cash Flow	2,405	2,769	2,988	2,144	2,018	2,035
Operating Cash Flow Growth	-14.07%	-7.32%	39.36%	6.27%	-0.84%	22.04%
Sale (Purchase) of Intangibles	-1,460	-2,506	-2,116	-1,742	-2,192	-2,182
Investment in Securities	547.46	-99.45	57.17	712.22	339.82	-577.07
Other Investing Activities	-284.55	-72.96	-14.44	-	-18.6	-
Investing Cash Flow	-1,272	-2,678	-2,073	-1,029	-1,870	-2,759
Short-Term Debt Issued	-	-	350	-	-	-
Long-Term Debt Issued	-	1,471	-	-	1,273	11,891
Total Debt Issued	3,229	1,471	350	-	1,273	11,891
Short-Term Debt Repaid	-	-	-350	-	-	-
Long-Term Debt Repaid	-	-	-1,000	-	-	-11,210
Total Debt Repaid	-2,275	-	-1,350	-	-	-11,210
Net Debt Issued (Repaid)	954.48	1,471	-1,000	-	1,273	680.63
Issuance of Common Stock	-	-	-	-	-	1,150
Repurchase of Common Stock	-1,199	-229.65	-304.76	-	-	-
Common Dividends Paid	-377.57	-376.47	-358.33	-333.32	-285.18	-397.84
Other Financing Activities	-521.8	-503.97	-485.67	-611.53	-602.24	53.99
Financing Cash Flow	-1,144	361.15	-2,149	-944.86	385.11	1,487
Net Cash Flow	-11.11	452.02	-1,234	169.7	532.37	762.48
Cash Interest Paid	270.42	159.57	169.17	170.14	130.43	103.2
Levered Free Cash Flow	-590.95	-1,759	-1,245	-1,384	-1,547	-1,087
Unlevered Free Cash Flow	-438.45	-1,637	-1,149	-1,288	-1,463	-993.85
Change in Working Capital	3,202	3,037	3,207	2,540	2,300	2,198

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q